News

Announcement: Dr. Peter Andersen Awarded Prestigious Scientific Prize

Dr. Peter Andersen, the Vice President of Vaccine Research and Development at Statens Serum Institut (SSI) and TBVI partner, has been awarded the prestigious Novo Nordisk prize for his work in TB vaccine development. The WGND interviewed Dr. Andersen for our TB R&D Weekly Update on March 8. Congratulations to Dr. Andersen!

For full story, click here.

More News
17 Sep 2019
Earlier this month, the NIH announced two new Funding Opportunity Annoucnements (FOAs) on the topic of Myeloid-Derived Suppressor Cells (MDSC) as potential therapeutic targets in TB/HIV co-infected patients. The purpose of these FOAs is to invite applications for support of innovative clinical,...
14 Aug 2019
FDA released the following press release on Wednesday, August 14th: The U.S. Food and Drug Administration today approved Pretomanid Tablets in combination with bedaquiline and linezolid for the treatment of a specific type of highly treatment-resistant tuberculosis (TB) of the lungs. “The threat of...
27 Jun 2019
-- Globe Newswire reported on June 20th -- Spero Therapeutics, Inc. , a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing treatments in high unmet need areas involving multi-drug resistant (MDR) bacterial infections and rare diseases, today...